Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04831255 · ClinicalTrials.gov registry record · Phase 1
ZILRETTA™ for Treatment of Idiopathic Adhesive Capsulitis
A Phase 1 study, sponsored by University of Virginia.
- Terminated
- Registry status
- Phase 1
- Development phase
- 39
- Enrollment target
NCT04831255 is a Phase 1 study that was terminated before completion, run by University of Virginia. The registered enrollment target is 39 participants.
The verdict
NCT04831255, a Phase 1 study, was terminated before completion, sponsored by University of Virginia.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 39 participants
- Enrollment target
Study Summary
Adhesive capsulitis is a fairly common orthopedic condition that causes pain and loss of range of motion. There are a variety of ways to treat adhesive capsulitis, one of them being an intra-articular steroid injection. This is done to help decrease the inflammatory response caused by adhesive capsulitis. In this study, all participants will receive an intra-articular glenohumeral injection of ZILRETTA and will be followed up with at four time points over 1 year to observe pain, function and range of motion following the injection.
Interventions
- DRUG triamcinolone acetonide extended-release injectable suspension
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 39 participants |
| Start Date | 2019-06-21 |
| Est. Completion | 2023-08-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04831255
The ClinicalTrials.gov registry entry for NCT04831255 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 39 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Virginia, which has 449 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which triamcinolone acetonide extended-release injectable suspension is the first listed.
NCT04831255 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04831255 about?
NCT04831255 is a clinical study titled "ZILRETTA™ for Treatment of Idiopathic Adhesive Capsulitis". Adhesive capsulitis is a fairly common orthopedic condition that causes pain and loss of range of motion. There are a variety of ways to treat adhesive capsulitis, one of them being an intra-articular steroid injection. This is done to help decrease the inflammatory response caused by adhesive capsu...
What is the current status of trial NCT04831255?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 39 participants. The study started on 2019-06-21. Estimated completion is 2023-08-31.
What interventions are being tested in trial NCT04831255?
The interventions under investigation include: triamcinolone acetonide extended-release injectable suspension (DRUG).
Who is sponsoring clinical trial NCT04831255?
This trial is sponsored by University of Virginia, which has 449 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.